Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDLN
MDLN logo

MDLN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
43.500
Open
43.050
VWAP
41.78
Vol
18.29M
Mkt Cap
55.19B
Low
39.830
Amount
764.13M
EV/EBITDA(TTM)
24.14
Total Shares
1.31B
EV
73.60B
EV/OCF(TTM)
--
P/S(TTM)
1.18
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.
Show More

Events Timeline

(ET)
2026-05-06
12:20:00
FDA Warns Medline Neurosurgical Products Have High Endotoxin Levels
select
link
2026-05-06
10:00:00
Medline Reports Q1 Revenue of $7.35B, Exceeds Expectations
select
2026-05-06
10:00:00
Raises FY26 Organic Sales View to 8.5%-9.5%
select
2026-04-24 (ET)
2026-04-24
10:20:00
FDA Revokes Approval for Several Medline Products
select
link
2026-04-16 (ET)
2026-04-16
15:50:00
Medline Signs Strategic Agreement with Symbotic for Warehouse Automation
select

News

seekingalpha
9.5
05-06seekingalpha
PinnedMedline Reports Strong Q1 2026 Earnings Amid Margin Pressures
  • Strong Sales Growth: Medline reported net sales of $7.4 billion in Q1 2026, reflecting an 11% year-over-year increase, driven by robust performance in Supply Chain Solutions despite rising cost pressures.
  • Adjusted EBITDA Decline: The adjusted EBITDA stood at $776 million, an 11% decline compared to the previous year, primarily due to increased costs of goods sold and incremental tariffs, indicating margin pressure even with sales growth.
  • Strategic Partnerships: Medline announced a partnership with Mohawk Medbuy Corporation to serve as the Prime Vendor for nine acute care hospitals, with implementation expected in the second half of 2026, enhancing its presence in the Canadian market.
  • Optimistic Outlook: The company raised its full-year 2026 organic sales growth guidance to a range of 8.5% to 9.5%, while maintaining adjusted EBITDA guidance at $3.5 billion to $3.6 billion, reflecting confidence in future market conditions.
seekingalpha
9.5
05-06seekingalpha
Medline Inc. Q1 Earnings Exceed Expectations
  • Earnings Beat: Medline Inc. reported a Q1 non-GAAP EPS of $0.33, exceeding expectations by $0.04, indicating strong operational performance that boosts investor confidence.
  • Significant Revenue Growth: The company achieved revenue of $7.35 billion, a 14.1% year-over-year increase, surpassing market expectations by $190 million, reflecting sustained demand and market share expansion in the healthcare sector.
  • Upgraded Sales Guidance: Medline raised its full-year 2026 organic sales guidance range to 8.5% to 9.5%, signaling optimism about future growth prospects, which may attract more investor interest.
  • Positive Stock Reaction: Following the earnings release, Medline's shares rose by 3%, demonstrating market recognition of its financial performance and potentially providing support for future capital initiatives.
seekingalpha
9.5
05-05seekingalpha
Medline Inc. Scheduled to Announce Q1 Earnings on May 6
  • Earnings Announcement: Medline Inc. is set to release its Q1 2023 earnings report on May 6 before the market opens, with consensus EPS estimated at $0.29 and revenue projected at $7.16 billion, indicating investor interest in the company's financial performance.
  • Cautious Risk Assessment: Despite the upcoming earnings report, analysts express caution regarding Medline's risk-reward profile, suggesting a lack of confidence in its future performance, which may influence investor decisions.
  • FDA Warning Impact: Medline recently received an FDA warning over faulty heart syringes, which could negatively affect its product reputation and sales, further exacerbating market concerns about its financial health.
  • Industry Dynamics: Ahead of Medline's earnings release, Goldman Sachs has cut its IPO forecast, reflecting a cautious outlook on the overall healthcare sector, which may impact Medline's market performance.
Newsfilter
3.5
05-04Newsfilter
Medline Launches Mpower to Enhance Supply Chain Resilience
  • Technological Innovation: Medline's Mpower™, a cloud-based AI supply chain technology, is designed to help healthcare providers predict and respond to potential disruptions before they impact patient care, representing a significant modernization of healthcare supply chain decision-making through collaboration with Microsoft.
  • Real-Time Optimization: As a digital control tower, Mpower integrates customer supply and demand data, predictive analytics, and workflow automation, with initial data showing over a 50% efficiency gain in order substitution workflows and decision-making compared to a five to seven-day baseline without Mpower.
  • User-Friendly Features: The system includes an integrated AI chat agent that allows users to ask questions, explore product alternatives, and streamline clinical approvals directly within the platform, leveraging Microsoft Office 365 and Azure's data security for quick and secure integration.
  • Phased Rollout: Mpower will be rolled out to Medline customers in phases throughout 2026, with additional capabilities planned as the platform evolves, aiming to help healthcare providers build more resilient, data-driven supply chains amid ongoing global complexities.
seekingalpha
8.5
04-27seekingalpha
Goldman Sachs Lowers 2026 IPO Forecast Amid Market Volatility
  • IPO Forecast Reduction: Goldman Sachs has revised its 2026 IPO forecast down from 120 to 100 deals, expecting total proceeds of $160 billion, primarily due to geopolitical uncertainties and increased volatility in the equity markets, indicating a fragile market environment.
  • Market Environment Analysis: While the macroeconomic backdrop remains supportive of IPO activities, Goldman flagged increased selectivity and downside risks to issuance, suggesting that investor confidence in new offerings may be waning, which could impact future fundraising capabilities.
  • Market Performance Overview: Since 2025, Venture Global leads the IPO market with a market cap of $60 billion, despite a 48% decline since its IPO, highlighting the high volatility and investment risks present in the current market.
  • Industry Dynamics: Among various IPOs, CoreWeave's 194% growth in market cap demonstrates strong market performance, while Figma faces a 53.25% year-to-date decline due to structural risks, reflecting the varying performances of companies in the current market environment.
PRnewswire
7.5
04-16PRnewswire
Medline Invests in Next-Gen Supply Chain Technology
  • Strategic Partnership: Medline has entered into a strategic agreement with AI robotics leader Symbotic to pilot next-generation warehouse automation technology in one of its 45 U.S. distribution centers in 2027, aiming to enhance the resilience and efficiency of the healthcare supply chain, thereby strengthening its competitive position in the medical industry.
  • Innovative Technology Application: The Symbotic system automates the picking, storage, and retrieval of items using intelligent autonomous robots, enabling rapid processing of inbound full pallets and constructing smart outbound pallets tailored to downstream needs, which is expected to significantly boost Medline's distribution speed and operational efficiency.
  • Enhanced Customer Service: Medline's Chief Supply Chain Officer, Sean Halligan, stated that this investment will help customers achieve higher operational, clinical, and financial goals, further solidifying Medline's leadership in medical products and supply chain solutions.
  • Ongoing Technology Investment: This partnership is part of Medline's continued investment in advanced technologies across its U.S. distribution center network, aimed at improving speed, accuracy, and scalability while enhancing employee safety and experience, ensuring the company maintains a competitive edge in a rapidly changing market.
Wall Street analysts forecast MDLN stock price to rise
14 Analyst Rating
Wall Street analysts forecast MDLN stock price to rise
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
42.00
Averages
47.92
High
52.00
Current: 0.000
sliders
Low
42.00
Averages
47.92
High
52.00
Deutsche Bank
Hold
to
Hold
downgrade
$48 -> $42
AI Analysis
2026-05-07
New
Reason
Deutsche Bank
Price Target
$48 -> $42
AI Analysis
2026-05-07
New
downgrade
Hold
to
Hold
Reason
Deutsche Bank lowered the firm's price target on Medline to $42 from $48 and keeps a Hold rating on the shares.
Citi
Patrick Donnelly
Buy
downgrade
$60 -> $55
2026-05-07
New
Reason
Citi
Patrick Donnelly
Price Target
$60 -> $55
2026-05-07
New
downgrade
Buy
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Medline to $55 from $60 and keeps a Buy rating on the shares. The firm reduced estimates post the Q1 report to reflect higher input costs.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDLN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Medline Inc (MDLN.O) is 30.30, compared to its 5-year average forward P/E of 38.72. For a more detailed relative valuation and DCF analysis to assess Medline Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
38.72
Current PE
30.30
Overvalued PE
55.38
Undervalued PE
22.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
18.19
Current EV/EBITDA
19.17
Overvalued EV/EBITDA
25.19
Undervalued EV/EBITDA
11.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.38
Current PS
1.15
Overvalued PS
1.98
Undervalued PS
0.79

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

quel sont le action pour short
Intellectia · 1 candidates
Quarter Eps Yoy Growth: <= -10.0%Rsi Category: overbought, moderatePe Ttm: >= 40Moving Average Relationship: PriceCrossDownMA20Quarter Price Change Pct: >= $25.00
Ticker
Name
Market Cap$
top bottom
MDLN logo
MDLN
Medline Inc
60.23B
give me a specific stock to put or call
Intellectia · 77 candidates
Price: $20.00 - $300.00Market Cap Category: large, megaMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $2.00Month Price Change Pct: >= $5.00Is Optionable: TrueMacd: bullish
Ticker
Name
Market Cap$
top bottom
PG logo
PG
Procter & Gamble Co
385.96B
SHEL logo
SHEL
Shell PLC
225.71B
ABT logo
ABT
Abbott Laboratories
200.34B
BHP logo
BHP
BHP Group Ltd
198.08B
GLW logo
GLW
Corning Inc
124.62B
AEM logo
AEM
Agnico Eagle Mines Ltd
120.32B

Whales Holding MDLN

D
Durable Capital Partners, LP
Holding
MDLN
+62.24%
3M Return
C
Capstone Investment Advisors, LLC
Holding
MDLN
+20.31%
3M Return
S
Schonfeld Strategic Advisors LLC
Holding
MDLN
+13.91%
3M Return
S
Soros Fund Management LLC
Holding
MDLN
+8.81%
3M Return
W
WCM Investment Management
Holding
MDLN
+7.08%
3M Return
H
HBK Investments L.P.
Holding
MDLN
+5.13%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Medline Inc (MDLN) stock price today?

The current price of MDLN is 42.01 USD — it has decreased -7.3

What is Medline Inc (MDLN)'s business?

Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.

What is the price predicton of MDLN Stock?

Wall Street analysts forecast MDLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDLN is47.92 USD with a low forecast of 42.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Medline Inc (MDLN)'s revenue for the last quarter?

Medline Inc revenue for the last quarter amounts to 7.35B USD, increased 10.66

What is Medline Inc (MDLN)'s earnings per share (EPS) for the last quarter?

Medline Inc. EPS for the last quarter amounts to 0.29 USD, decreased -27.50

How many employees does Medline Inc (MDLN). have?

Medline Inc (MDLN) has 45000 emplpoyees as of May 07 2026.

What is Medline Inc (MDLN) market cap?

Today MDLN has the market capitalization of 55.19B USD.